EU/3/11/867

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.

On 13 May 2011, orphan designation (EU/3/11/867) was granted by the European Commission to Fate Therapeutics LTD, United Kingdom, for allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute myeloid leukaemia.

Key facts

Active substance
Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
13/05/2011
Outcome
Withdrawn
EU designation number
EU/3/11/867

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Fate Therapeutics LTD
41 Chalton St, first floor
London NW1 1JD
United Kingdom
Tel. +44 (0)20 7554 2252
Fax +44 (0)20 7554 2201
E-mail: fate@fatetherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating